Advertisement


Yasmin H. Karimi, MD, on Large B-Cell Lymphoma: Follow-up on Subcutaneous Epcoritamab Monotherapy

2024 ASCO Annual Meeting

Advertisement

Yasmin H. Karimi, MD, of the University of Michigan Comprehensive Cancer Center, discusses 2.5-year follow-up data on epcoritamab monotherapy for patients with relapsed or refractory large B-cell lymphoma. The subcutaneous regimen continues to demonstrate durable responses (Abstract 7039).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
EPCORE NHL-1 was a phase 2 trial evaluating Epcoritamab, a CD20, CD3-bispecific antibody in the treatment of relapsed refractory large cell lymphoma in the second line and beyond setting. In this poster, we presented longer term follow-up results, MRD results, as well as results from the optimization cohort. In the study, patients with relapsed refractory disease were enrolled and treated with Epcoritamab step-up dosing with full dose given on cycle 1, day 15. In the optimization cohort, the dosing schema remained the same. However, CRS prophylaxis was 15 milligrams, dexamethasone, and 500 milliliters of hydration. In the optimization cohort, hospitalization for CRS monitoring after full dose treatment was not required. 157 patients with large B-cell lymphoma were treated in the expansion cohort. The median age was 68 years, and patients had a median of three prior lines of treatment. This was a heavily pretreated patient population with 39% of patients having received a prior CAR-T and 83% refractory to the last line of treatment. The overall response rate in the study was 59% with 41% experiencing a complete response. A median follow-up time of 31 months. The median duration of CR has not yet been reached. An estimated 54% of complete responders remained in CR at 30 months. In patients in complete response, 80% of patients achieved MRD negativity at cycle 3 and 92% of patients experienced MRD negativity at any time point as assessed by clonoSEQ MRD. The most common treatment emergent adverse events were cytokine release syndrome, occurring at 51% of patients, fatigue, fever, neutropenia, diarrhea, nausea, anemia, and infections. There were 29% of patients that had a grade three or higher serious infection, and 10% discontinued therapy due to infection. As this trial was conducted during the COVID-19 pandemic and the omicron variant, there were 32 cases of COVID and nine deaths due to COVID. In the optimization cohort, the uniform use of dexamethasone and hydration, the incidents and severity of CRS occurred in about 37% of patients, and with the majority being low grade. Most CRS occurred after the first full dose of treatment and CRS events all resolved. Hospitalization was not mandatory and was at the discretion of the investigator. 60% of patients received outpatient therapy and only one patient required subsequent inpatient admission. After outpatient treatment, the remaining CRS events were managed without hospitalization. In summary, with over 2.5 years of follow-up of single agent Epcoritamab in relapse refractory large cell lymphoma, including high risk patient populations with prior CAR-T and primary refractory disease, the data continues to show ongoing durable responses in patients who achieve a CR and 62% of patients remain in CR at two years. In the optimization cohort data, in addition to another abstract printed in ash with outpatient Epcoritamab lends support to the safety of fully outpatient administration.

Related Videos

Kidney Cancer

Laurence Albiges, MD, PhD, on Renal Cell Carcinoma: Biomarker Analysis of the IMmotion010 Study

Laurence Albiges, MD, PhD, of Gustave Roussy, Université Paris-Saclay, discusses phase III findings showing that high baseline serum KIM-1 levels were associated with poorer prognosis but improved clinical outcomes with atezolizumab vs placebo in patients with renal cell carcinoma at increased risk of recurrence after resection. Increased post-treatment KIM-1 levels were found to be associated with worse disease-free survival (Abstract 4506).

Leukemia

Mazyar Shadman, MD, MPH, on Chronic Lymphocytic Leukemia: Recruiting for the CELESTIAL-TNCLL Study

Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center, discusses an ongoing phase III study of the BCL2 inhibitor sonrotoclax plus zanubrutinib vs venetoclax and obinutuzumab for patients with treatment-naive chronic lymphocytic leukemia. The investigators are recruiting internationally (see NCT06073821; Abstract TPS7087).

Issues in Oncology

Andrew Srisuwananukorn, MD, and Alexander T. Pearson, MD, PhD, on Artificial Intelligence in the Clinic: Understanding How to Use This 21st Century Tool

Andrew Srisuwananukorn, MD, of The Ohio State University, and Alexander T. Pearson, MD, PhD, of the University of Chicago, discuss the use of artificial intelligence (AI) in the clinic, its potential benefits in diagnosis and treatment, resources available to help physicians learn more about AI, and what’s coming for the next generation of medical school students.

Palliative Care

Joseph A. Greer, PhD, on Lung Cancer: Telehealth vs In-Person Palliative Care

Joseph A. Greer, PhD, of Massachusetts General Hospital and Harvard Medical School, discusses study findings showing the merits of delivering early palliative care via telehealth vs in person to patients with advanced lung cancer. Using telemedicine in this way may potentially improve access to and more broadly disseminate this evidence-based care model (LBA3).

Skin Cancer

Christian U. Blank, MD, PhD, on Melanoma: Potentially Practice-Changing Results From the NADINA Trial

Christian U. Blank, MD, PhD, of the Netherlands Cancer Institute, discusses findings of an investigator-initiated phase III trial showing that neoadjuvant ipilimumab plus nivolumab followed by response-driven adjuvant treatment improved event-free survival in patients with macroscopic, resectable stage III melanoma compared with adjuvant nivolumab (LBA2)

Advertisement

Advertisement




Advertisement